The main functions of the Council on Science and Public Health (CSAPH) are to advise on substantial and promising developments, and to assist in developing policy positions on scientific aspects of medicine, public health, and biomedical research that warrant the attention of the profession, the public, and the public/private sector.
The primary method of developing evidence-based policy positions and recommendations is the drafting of reports for the House of Delegates. Topics for CSAPH reports can be the result of AMA House of Delegates action or chosen and initiated, in the case of an emerging scientific or public health area or policy gap, by the Council.
CSAPH bases the policy recommendations presented in reports on a review and evaluation of relevant sources detailing the evidence-base and current knowledge of a topic. Sources include peer-reviewed literature, expert papers, commentaries, special publications, expert meeting and workshop proceedings, and stakeholder outreach.
Reports
Some topics that have been addressed by CSAPH include environmental health, various drug issues, vaccinations, genetic and precision medicine, child safety, and public health matters.
- Child safety CSAPH reports
- Environmental health CSAPH reports
- Genetic medicine CSAPH reports
- Physician safety CSAPH reports
- Prescription drugs CSAPH reports
- Public health CSAPH reports
- Vaccinations CSAPH reports
Featured reports
- Marketing Guardrails for the "Over-Medicalization" of Cannabis Use (PDF) CSAPH report 6-I-23
- Improving Research Standards, Approval Processes, and Post-Market Surveillance Standards for Medical Devices (PDF) CSAPH report 02-A-23
- Transformation of Rural Community Public Health Systems (CSAPH Report 2-A-22)
- Drug Shortages: 2021 Update (CSAPH 1-N-21)
- Full Commitment by our AMA to the Betterment and Strengthening of Public Health Systems (Resolution 401-JUN-21) (CSAPH 2-N-21)
- Physician Involvement in State Regulations of Motor Vehicle Operation and/or Firearm Use by Individuals with Cognitive Deficits Due to Traumatic Brain Injury (CSAPH 3-N-21)
- Pharmacovigilance (Res 518-A-19, Chemical Variability in Pharmaceutical Products) (CSAPH 4-N-21)
- Dietary Supplements: Update on Regulation, Industry, and Product Trends (CSAPH-report 3-I-20)
- Drug Shortages: Update PDF, 453.5 KB (CSAPH-report 2-A-19)
- FDA Expedited Review Programs and Processes PDF, 182.6 KB (CSAPH-report 2-I-18)
- Aligning Clinical and Financial Incentives for High-Value Care PDF, 313.37 KB (CSAPH/CMS joint report I-18)
- Physician’s Role in Firearm Safety PDF, 147.7 KB (CSAPH-report 4-A-18)
- Prescription Drug Donation PDF, 131.53 KB (CSAPH-report 3-A-18)
- Improving Screening and Treatment Guidelines for Domestic Violence Against Lesbian, Gay, Bisexual, Transgender, Queer/Questioning, and Other Individuals PDF, 151.23 KB (CSAPH-report 1-I-18)
- Tobacco Harm Reduction PDF, 164.95 KB (CSAPH-report 5-A-18)
